Myxofibrosarcoma
ICD-10 C49.9 · ICD-11 2B53.0

Treatment of Unresectable Locally Advanced or Metastatic Myxofibrosarcoma

When myxofibrosarcoma is unresectable, locally advanced, or has spread to distant sites, systemic treatment becomes the primary focus. This scenario carries a very poor prognosis and requires a structured, evidence-based approach.

Clinical Situation

Disease has progressed beyond surgical control — either through local advancement that renders resection unfeasible or through metastatic spread. This places the patient in a high-risk setting where systemic therapy is the main treatment modality.

First-line treatment approach: An anthracycline-based regimen is the established starting point for systemic therapy in this setting. Whether additional agents are combined depends on factors addressed in the full protocol — the complete selection criteria, sequencing, and regimen details are not shown here.

Treatment Goal

The primary aim is to achieve a measurable partial tumor response on imaging.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/diagnostics13193022

  1. The development of unresectable locally advanced or metastatic MFS is assocaited with a very poor prognosis.
  2. Like other STS subtypes, anthracycline, with or without ifosfamide, is the first-line treatment for advanced MFS.
  3. A randomized, controlled, phase 3 trial, comparing an anthracycline and ifosfamide combination (A + I) versus anthracycline alone, showed a significant improvement in progression-free survival (PFS) in the combination treatment group, but with no improvement in OS.
  4. A recent randomized open-label phase 3 trial suggested that A + I should remain the regimen to choose whenever neoadjuvant chemotherapy is used in patients with high-risk STS.
  5. A partial response (PR) was observed in 4 (31%) of the 13 patients.
View source ↗